Gonadotrophin releasing hormone agonist with low dose human chorionic gonadotrophin co-triggers versus gonadotrophin releasing hormone agonist alone for reducing the risk of ovarian hyperstimulation in women with polycystic ovarian disease.
Arafa, A., Mohamed, M., Aboulserour, A., Gebreel, M. (2022). Gonadotrophin releasing hormone agonist with low dose human chorionic gonadotrophin co-triggers versus gonadotrophin releasing hormone agonist alone for reducing the risk of ovarian hyperstimulation in women with polycystic ovarian disease.. EKB Journal Management System, 3(7), 96-101. doi: 10.21608/aimj.2022.117755.1810
Ahmed Elsayed Arafa; Mofeed Fawzy Mohamed; Ahmed Gamal Aboulserour; Mohamed Gebreel. "Gonadotrophin releasing hormone agonist with low dose human chorionic gonadotrophin co-triggers versus gonadotrophin releasing hormone agonist alone for reducing the risk of ovarian hyperstimulation in women with polycystic ovarian disease.". EKB Journal Management System, 3, 7, 2022, 96-101. doi: 10.21608/aimj.2022.117755.1810
Arafa, A., Mohamed, M., Aboulserour, A., Gebreel, M. (2022). 'Gonadotrophin releasing hormone agonist with low dose human chorionic gonadotrophin co-triggers versus gonadotrophin releasing hormone agonist alone for reducing the risk of ovarian hyperstimulation in women with polycystic ovarian disease.', EKB Journal Management System, 3(7), pp. 96-101. doi: 10.21608/aimj.2022.117755.1810
Arafa, A., Mohamed, M., Aboulserour, A., Gebreel, M. Gonadotrophin releasing hormone agonist with low dose human chorionic gonadotrophin co-triggers versus gonadotrophin releasing hormone agonist alone for reducing the risk of ovarian hyperstimulation in women with polycystic ovarian disease.. EKB Journal Management System, 2022; 3(7): 96-101. doi: 10.21608/aimj.2022.117755.1810